Roche
NEWS
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
The U.S. Food and Drug Administration (FDA) granted Genentech, a Roche company, Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) for hemophilia A without factor VIII inhibitors.
Roche said it has gained 510(k) clearance from the U.S. Food and Drug Administration for cobas CT/NG for use on the cobas 6800/8800 Systems for the detection of chlamydia and gonorrhea in both symptomatic and asymptomatic patients.
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
According to news reports, a six-year-old girl in North Texas was provided Tamiflu and had a rare reaction that affected her nervous system.
Here’s a look at the seven best life science companies to work for in 2018.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
JOBS
IN THE PRESS